The Prevalence of Antifungal Agents Administration in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study
-
Mona Kargar
,
Alireza Ahmadvand
,
Milad Ahmadvand
,
Molouk Hadjibabaie
,
Kheirollah Gholami
,
Seyed Hamid Khoee
,
Mohammad Reza Javadi
,
Ardeshir Ghavamzadeh
Abstract
Background: Invasive fungal infections (IFIs) are chief infectious complications in patients undergoing hematopoietic stem cell transplantation (HSCT). However, the diagnosis of fungal infections is difficult, and often empiric treatment initiates. Since there is no data available on the prevalence of antifungal drugs administration in allogeneic HSCT recipients in Iran, we decided to conduct this study.
Methods: This study was a retrospective review of records of patients who received allogeneic HSCT in the Hematology-Oncology, Bone Marrow Transplantation center at Shariati Hospital in Tehran, between August 2009 and August 2010.
Results: Sixty (73.1%) patients consist of 41 men (68.3%) with mean age of 26.3 (± 1.2) years received allogeneic HSCT. Patients received prophylaxis with fulconazole however; in 28 patients (46.7%) it was switched to low dose amphotericin B. Fifteen patients (25%) received treatment with antifungal agents. Amphotericin B was the empiric agent administered. In 3 patients treatment was switched to voriconazole. Neither positive culture nor direct microscopic evidence was available from the obtained specimen. Only in one patient the result of serum galactomannan assay was positive. There were no significant differences in neutropenia duration (P value: 0.54), length of hospital stay (P value: 0.27) and number of patients developed graft versus host disease (P value: 0.07) between patients received antifungal agents with those who did not receive treatment.
Conclusion: In this study HSCT recipients received antifungal agents for prophylaxis. Twenty five percent of patients received treatment with antifungal agents empirically. Improvement in diagnosis of these infections can be helpful and lead to targeted therapy. We suggest larger prospective trials for better assessment of antifungal agent administration.
Rieger C, Rieger H, Kolb H, Peterson L, Huppmann S, Fiegl M, et al. Infectious complications after allogeneic stem cell transplantation: incidence in matched‐related and matched‐unrelated transplant settings. Transpl Infect Dis. 2009; 11(3):220-6.
Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant. 2002; 8(9):512-20.
Daly A, McAfee S, Dey B, Colby C, Schulte L, Yeap B, et al. Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant. 2003; 9(6):373-82.
Saavedra S, Jarque I, Sanz G, Moscardó F, Jiménez C, Martin G, et al. Infectious complications in patients undergoing unrelated donor bone marrow transplantation: experience from a single institution. Clin Microbiol Infect. 2002; 8(11):725-33.
George B, Mathews V, Viswabandya A, Srivastava A, Chandy M. Infections in children undergoing allogeneic bone marrow transplantation in India. Pediatr Transplant. 2006; 10(1):48-54.
Wingard JR. New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients. Best Practice & Research Clinical Haematology. 2007; 20(1):99-107.
Wilson DT, Drew RH, Perfect JR. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. Mycopathologia. 2009; 168(6):313-27.
Nucci M, Anaissie E. Fungal infections in hematopoietic stem cell transplantation and solid-organ transplantation--focus on aspergillosis. Clin Chest Med. 2009; 30(2):295.
Camps IR. Risk factors for invasive fungal infections in haematopoietic stem cell transplantation. Int J Antimicrob Agents. 2008; 32:S119.
Sohn HS, Lee T-J, Kim J, Kim D. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. Clin Ther. 2009; 31(5):1105-15.
Martino R, Subirá M, Rovira M, Solano C, Vázquez L, Sanz GF, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol. 2002; 116(2):475-82.
Leather HL, Wingard JR. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. Blood Rev. 2006; 20(5):267-87.
Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol. 2007; 139(4):519-31.
Klepser M. The value of amphotericin B in the treatment of invasive fungal infections. J Crit Care. 2011; 26(2):225. e1-. e10.
Huang X, Chen H, Han M, Zou P, Wu D, Lai Y, et al. A multi-center, randomized, open label study comparing the efficacy and safety of micafungin vs. itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012.
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis. 2008; 46(12):1813-21.
De Pauw B. Antifungal Therapy. Transplant Proc. 2011; 43(6):2461-2.
Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34(6):730-51.
Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents. 2006; 27:12-6.
Chen SC, Playford EG, Sorrell TC. Antifungal therapy in invasive fungal infections. Curr Opin Pharmacol. 2010; 10(5):522-30.
Einollahi B, Lessan-Pezeshki M, Pourfarziani V, Nemati E, Nafar M, Pour-Reza-Gholi F, et al. Invasive fungal infections following renal transplantation: a review of 2410 recipients. Annals of transplantation: quarterly of the Polish Transplantation Society. 2008; 13(4):55.
Marjani M, Tabarsi P, Najafizadeh K, Farokhi F, Sharifkashani B, Motahari S, et al., editors. Pulmonary aspergillosis in solid organ transplant patients: a report from Iran. Transplant Proc; 2008.
Sharifipour F, Rezaeetalab F, Naghibi M, editors. Pulmonary fungal infections in kidney transplant recipients: an 8-year study. Transplant Proc; 2009: Elsevier.
Steib-Bauert M, Knoth H, Dörje F, Strehl E, Rothe U, Maier L, et al. Hospital use of systemic antifungal drugs. BMC Pharmacology and Toxicology. 2005; 5(1):1.
Segal BH, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, Walsh TJ, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis. 2007; 44(3):402-9.
Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B prophylaxis against invasivei Aspergillus infections in allogeneic marrow transplantation. The American journal of medicine. 1991; 91(5):484-92.
Koh L, Kurup A, Goh Y, Fook‐Chong S, Tan P. Randomized trial of fluconazole versus low‐dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol. 2002; 71(4):260-7.
Cordonnier C, Mohty M, Faucher C, Pautas C, Robin M, Vey N, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents. 2008; 31(2):135-41.
Perrella A, Esposito C, Pisaniello D, D'Alessio L, Perrella O, Marcos A, et al., editors. Role of Liposomal Amphotericin B Prophylaxis After Liver Transplantation Compared With Fluconazole for High-Risk Patients. Impact on Infections and Mortality Within one Year. Transplant Proc; 2012: Elsevier.
Kelsey S, Goldman J, McCann S, Newland A, Scarffe JH, Oppenheim B, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant. 1999; 23(2):163.
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356(4):348-59.
Barnes RA, Stocking K, Bowden S, Poynton MH, White PL. Prevention and Diagnosis of Invasive Fungal Disease in high-risk patients within an integrative care pathway. J Infect. 2013.
Chan TS, Hwang YY, Gill H, Cheung WW, Tse E, Leung AY, et al. Anti‐fungal drug usage in hematologic patients during a 4‐year period in an Asian university teaching hospital. Intern Med J. 2012.
Goldberg E, Gafter-Gvili A, Robenshtok E, Leibovici L, Paul M. Empirical antifungal therapy for patients with neutropenia and persistent fever: systematic review and meta-analysis. Eur J Cancer. 2008; 44(15):2192-203.
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46(3):327-60.
Ji Y, Xu L-p, Liu D-h, Chen Y-h, Han W, Zhang X-h, et al. Positive results of serum galactomannan assays and pulmonary computed tomography predict the higher response rate of empirical antifungal therapy in patients undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17(5):759-64.
| Files | ||
| Issue | Vol 7, No 3 (2013) | |
| Section | Articles | |
| Keywords | ||
| Amphotericin B Antifungal agents Peripheral blood stem cell transplantation Retrospective Studies | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
